Anika Therapeutics (ANIK) FCF Margin (2010 - 2026)
Anika Therapeutics (ANIK) reported FCF Margin of 16.55% for Q1 2026, down 1414.0% year-over-year from 1.26% in Q1 2025, and down 226.45% quarter-over-quarter from 13.09% in Q4 2025.
Anika Therapeutics (ANIK) FCF Margin (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of FCF Margin data on file, last reported at 16.55% in Q1 2026.
- FCF Margin for Q1 2026 came in at 16.55%, down 1414.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 5.38% (up 121.0% YoY), and the FY2025 annual result was 9.33%, up 535.0% from the prior year.
- FCF Margin fell to 16.55% in Q1 2026 per ANIK's latest filing, from 13.09% in the prior quarter.
- Over five years, FCF Margin peaked at 39.99% in Q3 2025 and troughed at 221.11% in Q4 2023.
- A 5-year average of 23.62% and a median of 2.58% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2024: FCF Margin slumped 20430 bps in 2022, then soared 24519 bps in 2024.
- A 5-year view of FCF Margin shows it stood at 191.25% in 2022, then slipped by 16 bps to 221.11% in 2023, then surged by 111 bps to 24.08% in 2024, then slumped by 46 bps to 13.09% in 2025, then sank by 226 bps to 16.55% in 2026.
- Business Quant data shows ANIK's FCF Margin at 16.55% in Q1 2026, 13.09% in Q4 2025, and 39.99% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -5.22% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 12.86% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 46.39% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 16.78% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -2.77% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -429.96% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 13.24% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 32.62% |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | -16.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.55% |
| Dec 31, 2025 | 13.09% |
| Sep 30, 2025 | 39.99% |
| Jun 30, 2025 | -14.10% |
| Mar 31, 2025 | -2.42% |
| Dec 31, 2024 | 24.08% |
| Sep 30, 2024 | 12.86% |
| Jun 30, 2024 | -18.42% |
| Mar 31, 2024 | -2.58% |
| Dec 31, 2023 | -221.11% |
| Sep 30, 2023 | 7.13% |
| Jun 30, 2023 | -15.72% |
| Mar 31, 2023 | -13.20% |
| Dec 31, 2022 | -191.25% |
| Sep 30, 2022 | 2.53% |
| Jun 30, 2022 | 2.89% |
| Mar 31, 2022 | -8.71% |
| Dec 31, 2021 | 13.06% |
| Sep 30, 2021 | 11.57% |
| Jun 30, 2021 | 5.59% |